Cite
Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis.
MLA
Mittal, Abhenil, et al. “Three-Year Disease-Free Survival in Randomized Trials of Neoadjuvant Chemotherapy and HER2-Targeted Therapy in Breast Cancer: A Meta-Analysis.” Critical Reviews in Oncology/Hematology, vol. 181, Jan. 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.critrevonc.2022.103880.
APA
Mittal, A., Tamimi, F., Molto, C., Meti, N., Al-Showbaki, L., Wilson, B. E., & Amir, E. (2023). Three-year disease-free survival in randomized trials of neoadjuvant chemotherapy and HER2-targeted therapy in breast cancer: A meta-analysis. Critical Reviews in Oncology/Hematology, 181, N.PAG. https://doi.org/10.1016/j.critrevonc.2022.103880
Chicago
Mittal, Abhenil, Faris Tamimi, Consolacion Molto, Nicholas Meti, Laith Al-Showbaki, Brooke E. Wilson, and Eitan Amir. 2023. “Three-Year Disease-Free Survival in Randomized Trials of Neoadjuvant Chemotherapy and HER2-Targeted Therapy in Breast Cancer: A Meta-Analysis.” Critical Reviews in Oncology/Hematology 181 (January): N.PAG. doi:10.1016/j.critrevonc.2022.103880.